Ash Access Technology, Inc. and Commercial Partner AngioDynamics (ANGO) Highlight Results From Preliminary Study of Centros(TM)
1/25/2008 9:24:50 AM
More...
|
Ash Access Technology, Inc. Completes Patient Enrollment in AZEPTIC Trial for Zuragen(R)
1/25/2008 9:21:44 AM
More...
|
Ash Access Technology, Inc. Appoints Dr. Al Guillem As Vice President, Scientific And Quality Affairs
1/12/2007 10:46:21 AM
More...
|
Ash Access Technology, Inc. Investigational Antimicrobial / Antithrombotic Therapy (Zuragen(TM)) Pivotal Clinical Trial Begins
10/3/2006 10:30:33 AM
More...
|
Ash Access Technology, Inc. Partners With DaVita Clinical Research To Conduct Pivotal FDA Clinical Trial
2/16/2006 12:58:33 PM
More...
|
Ash Access Technology, Inc. Announces a Private Fund Managed By Bear Stearns And Other New Investors Have Subscribed To Their $6M Series B Round Of Financing
1/24/2006 1:28:35 PM
More...
|
FDA Notifies Ash Access Technology, Inc. Of Approved IDE For Final Formulation Of "MethLock(TM)," A New Antimicrobial, Anti-Biofilm Catheter Lock Expected To Outperform Heparin
10/19/2005 5:13:05 PM
More...
|
FDA Approves Clinical Trial For Ash Access Technology, Inc.'s MethLock(TM) Solution
10/19/2005 5:09:59 PM
More...
|
Ash Access Technology, Inc. Awarded a $2.7M SBIR Fast-Track Grant From National Institutes of Health (NIH) NIDDK To Fund The Imminent Clinical Trial Of The Company's Catheter Lock Solution, "MethLock(TM)," With Its Antimicrobial And Anti-Biofilm Properties
10/19/2005 5:09:20 PM
More...
|